Please use this identifier to cite or link to this item:
http://repository.kln.ac.lk/handle/123456789/27930
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chern, B. | - |
dc.contributor.author | Pinto, D. | - |
dc.contributor.author | Lum, J.H. | - |
dc.contributor.author | Parameswaran, R. | - |
dc.date.accessioned | 2024-07-26T10:16:48Z | - |
dc.date.available | 2024-07-26T10:16:48Z | - |
dc.date.issued | 2024 | - |
dc.identifier.citation | Biomedicines.2024;12(6):1304. | en_US |
dc.identifier.issn | 2227-9059 (Electronic) | - |
dc.identifier.uri | http://repository.kln.ac.lk/handle/123456789/27930 | - |
dc.description | Not indexed in MEDLINE. | en_US |
dc.description.abstract | IMPORTANCE Poorly differentiated cancer (PDC) and anaplastic thyroid cancer (ATC) have an aggressive course of disease with limited treatment options. The expression of programmed cell death ligand-1 (PD-L1) has been used to determine the responses of many cancers to immunotherapy. The aim of the study was to investigate the expression of PD-L1 in a cohort of patients with PDC and ATC to assess their suitability for immunotherapy. Data, settings, and participants: This study is a retrospective cohort review of patients treated for PDC and ATC treated at a tertiary referral institution during the period 2000-2020. PD-L1 22C3 pharmDx qualitative immunohistochemistry was performed on formalin-fixed, paraffin-embedded (FFPE) specimens of tumours to detect the presence of the PD-L1 protein.MAIN OUTCOME MEASURES The percentage of tumours that were positive for PD-L1 immunohistochemistry and the PD-L1 protein expression as measured by using the Tumour Proportion Score (TPS). Secondary outcomes studied were the associations between demographic, clinicopathological, treatment and disease outcomes and PD-L1 expression.RESULTS Nineteen patients (12F:7M) with a mean age of 65.4 (±14.3 SD) years were diagnosed with PDC in 4 (21%) and fifteen were diagnosed with ATC (79%) during the study period. Fifteen (79%) patients underwent some form of surgery, with R0 resection achieved in only three of the fifteen (20%) patients. Overall, PD-L1 expression was seen in seven of the fifteen (47%) of the patients with ATC, with no positivity seen in the patients with PDC. PD-L1 expression had no impact on treatment modality and positive expression was not significantly associated with stage of disease, metastasis, or survival.CONCLUSION Nearly half of patients with ATC express PD-L1 and may be amenable to immunotherapy with pembrolizumab. | en_US |
dc.language.iso | en | en_US |
dc.publisher | MDPI AG | en_US |
dc.subject | PD-L1 | en_US |
dc.subject | Anaplastic | en_US |
dc.subject | Cancer | en_US |
dc.subject | Immunotherapy | en_US |
dc.subject | Poorly differentiated | en_US |
dc.subject | Thyroid | en_US |
dc.title | Nearly half of patients with anaplastic thyroid cancer may be amenable to immunotherapy. | en_US |
dc.type | Article | en_US |
Appears in Collections: | Journal/Magazine Articles |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
biomedicines-12-01304.pdf | 1.86 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.